Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Vera Therapeutics, Inc.NASDAQ: VERA
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $52.41M rose 138.8% year over year, behind the +144.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 34.0% from the prior quarter. Over 3 fiscal years it compounded at +66.0% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +144.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $52.41M+34.0% QoQ
- Last fiscal yearDec 2025
- $100.22M+144.4% YoY
- LTMJun 2026
- $153.89M+144.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +138.8% | -100.0% | -238.8 pp |
| 1 year | +144.4% | -100.0% | -244.4 pp |
| 3-year CAGR | +66.0% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 100.22M USD
- Year-over-year change
- +144.4%
- 4-year CAGR
- +70.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.22M | +144.4% |
| FY2024 | 2024-12-31 | 41M | +72.4% |
| FY2023 | 2023-12-31 | 23.79M | +8.6% |
| FY2022 | 2022-12-31 | 21.91M | +83.8% |
| FY2021 | 2021-12-31 | 11.92M | — |
Selling, General & Admin vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 selling, general & admin of $153.89M is the 3rd highest of the 10 companies compared; the peer median is $62.81M.
- Its year-over-year change of +144.6% is the highest of 10, against a peer median of +19.2%.
- Over three fiscal years its annual growth of +66.0% compares with a peer median of +22.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $297.6M | +19.2% | +31.0% | 64.1% | |
| LTM Mar 2026 | $236.26M | +113.2% | +19.5% | 64.0% | |
| LTM Jun 2026 | $153.89M | +144.6% | +66.0% | — | |
| LTM Jun 2026 | $99.69M | -4.4% | -6.7% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M | +17.2% | +94.2% | 1041.9% |
| LTM Mar 2026 | $62.81M | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $46.46M | +34.5% | +22.2% | — | |
| LTM Jun 2026 | $44.15M | +49.3% | +72.0% | 2318.8% | |
| LTM Mar 2026 | $37.43M | +18.7% | +65.2% | — | |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
| Peer median (excluding VERA) | $62.81M | +19.2% | +22.2% | 167.0% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.